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Abstract: Light-activated ruthenium polypyridyl anticancer
prodrugs often suffer from poor water solubility, poor selec-
tivity, and/or ill-defined intracellular targets. Coordination of
the d- or l-glucose thioether ligand 3 (2-(2-(2-(methylthio)-
ethoxy)ethoxy)ethyl-b-glucopyranoside) to the highly lipo-
philic ruthenium complex [Ru(tpy)(dppn)(H2O)]
2+ ([1]2+ ;
dppn=benzo[i]dipyrido-[3,2-a :2’,3’-c]phenazine, tpy=
2,2’:6’,2’’-terpyridine) solved all these problems at once. The
two enantiomers of [Ru(tpy)(dppn)(3)][PF6]2, [d-2][PF6]2 and
[l-2][PF6]2, were soluble in water, which allowed the influ-
ence of the chirality of the glucose moiety on uptake, toxici-
ty, and intracellular localization of the prodrug to be probed
without changing any other physicochemical properties.
Both compounds showed mild, but different, cytotoxicity in
A549 (human lung carcinoma) and MCF-7 (human breast ad-
enocarcinoma) cancer cells in the dark, whereas following
low doses of visible light irradiation (3.1 J cm2 at l =
454 nm), a similar, but high cytotoxicity (EC50 < 1 mm), was
observed. Irrespective of the chirality, both slightly emissive
Ru complexes were found in the mitochondria, and two
modes of action may contribute to light-induced cell death:
1) the glucose thioether ligand is photosubstituted by water,
thus [1]2+ , which interacts with DNA at an exceptionally
high 400:1 base pair/Ru ratio, is released; 2) both [1]2+ and
[2]2+ produce massive amounts of singlet oxygen, which
leads to very efficient photodynamic DNA cleavage.
Introduction
One of the major challenges in the development of new anti-
cancer drugs is to improve their selectivity. A common strategy
to better differentiate normal proliferating cells from malignant
cells is to develop drugs that target specific hallmarks of
cancer cells, such as aerobic glycolysis. First described by War-
burg,[1] cancer cells use glycolysis for their energy production,
and therefore have a higher demand for simple sugars such as
d-glucose. The cell membrane is impermeable to polar mole-
cules so specific membrane transporters control glucose
uptake (GLUT and SGLT). These transporters are overexpressed
in many types of cancer cell, which aids d-glucose penetration
into the cell, and also provides a method to target imaging or
therapeutic compounds to cancer cells.[2] For example, 2-
deoxy-2-(18F)fluoro-d-glucose (18-FDG) is a common radiotracer
used in clinics to image tumors in vivo.[3]
Conjugating d-glucose or other GLUT substrates to organ-
ic[3,4] or inorganic[5] anticancer compounds is a rapidly expand-
ing cancer-targeting strategy. Several methods have been pro-
posed to assess the benefits of d-glucose functionalization of
an anticancer drug. Enhanced uptake is usually demonstrated
indirectly, for example by comparing glucose-functionalized
drugs to their aglycon counterparts,[6] or by competitive inhibi-
tion experiments with d-glucose.[7] However, these methods
usually ignore the difference in water solubility between the
glycoconjugates and their aglycon analogues, which can have
a major influence on the drug uptake, localization, and/or
mode-of-action for many compounds. Comparing the biologi-
cal effects of a glycoconjugate on different cell lines with dif-
ferent expressions of glucose transporters is another alterna-
tive.[8] However, depending on the cell line different glucose
transporters may be overexpressed,[9] which complicates the
interpretation of such experiments. Finally, adding glucose-
transporter inhibitors to switch off the uptake of glucose-func-
tionalized compounds is also possible.[10] However, synergies
between biologically active compounds have been demon-
strated on multiple occasions,[11] and it may be difficult to dis-
tinguish impaired drug uptake due to the inhibitors from the
cytotoxicity of the inhibitor itself.[12]
To solve these biases, we propose a new approach that di-
rectly compares the activity of the d- and l-glucose conjugates
[a] L. N. Lameijer, Dr. S. L. Hopkins, T. G. Brev, S. H. C. Askes, Dr. S. Bonnet
Leiden Institute of Chemistry, Leiden University
Gorlaeus Laboratories, P.O. Box 9502, 2300 RA Leiden (The Netherlands)
E-mail : bonnet@chem.leidenuniv.nl
Supporting information for this article is available on the WWW under
http://dx.doi.org/10.1002/chem.201603066.
 2016 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA.
This is an open access article under the terms of Creative Commons Attri-
bution NonCommercial License, which permits use, distribution and repro-
duction in any medium, provided the original work is properly cited and is
not used for commercial purposes.
Chem. Eur. J. 2016, 22, 1 – 9  2016 The Authors. Published by Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim1 &&
These are not the final page numbers! 
Full PaperDOI: 10.1002/chem.201603066
of achiral, highly lipophilic ruthenium compound [Ru(tpy)-
(dppn)(H2O)]
2+ ([1]2+ ; dppn=benzo[i]dipyrido-[3,2-a :2’,3’-
c]phenazine, tpy=2,2’:6’,2’’-terpyridine). Unlike d-glucose, l-
glucose is not a substrate for the glucose-transport system.[13]
Our basic assumption was that an l-glucose-modified drug
would have the same structural properties and water solubility
as its d-glucose analogue, but would not be recognized by cel-
lular enzymes, therefore it may be possible to probe the bio-
logical effects of the d-glucose functional group without the
experimental biases mentioned above. Compound [1]2+ has
another interesting property: it belongs to a family of metallo-
drugs that can be activated by visible-light irradiation.[14] Light-
activatable anticancer compounds may improve the selectivity
of anticancer treatments by an external trigger that can limit
the toxicity of the treatment to the time and place of light irra-
diation.[15]
We designed two light-activatable prodrugs [d-2]2+ and [l-
2]2+ ([Ru(tpy)(dppn)(d-3)]2+ and [Ru(tpy)(dppn)(l-3)]2+ , respec-
tively; 3 is a thioether ligand covalently linked to d- or l-glu-
cose that binds to ruthenium via a thermally stable Ru···S coor-
dination bond, see Figure 1). The synthesis, photochemistry,
and biological evaluation of these enantiomeric ruthenium
compounds is reported, and their cytotoxicity, cellular distribu-
tion, and mode-of-action are discussed.
Results and Discussion
Synthesis
The thioether glucose conjugates d-3 and l-3 (Scheme 1) were
synthesized from d- and l-glucose, respectively, according to
Schmidt’s methodology (Scheme S1 in the Supporting Informa-
tion).[16] As expected both ligands had the same physical and
spectroscopic properties, except for their opposite sign of opti-
cal rotation (d-3 : [a]20D =10.0 (c=1.00 in MeOH); l-3 : [a]20D =
+11.8 (c=1.00 in MeOH)) and their different retention times
for chiral HPLC (Figures S17 and S18 in the Supporting Infor-
mation). Next, the ligands d-3 or l-3 were coordinated to
ruthenium (Scheme 1). Isolation of the aqua complex [1][PF6]2
was necessary, and further reaction with a three-fold excess of
d-3 or l-3 under mild conditions (acetone, 50 8C) afforded the
d- or l-glucose conjugates, [d-2][PF6]2 and [l-2][PF6]2, respec-
tively, in moderate yields. Unlike [1][PF6]2 and [Ru(t-
py)(dppn)Cl]Cl ([4][Cl]), which are virtually insoluble in water,
[d-2][PF6]2 and [l-2][PF6]2 can be dissolved in water, even in ab-
sence of DMSO.
Photochemistry
The photoreactivity of the water-soluble thioether complex [d-
2][PF6]2 was tested under different conditions. Figure 2 shows
the evolution of the UV/Vis spectrum of [d-2][PF6]2 upon blue-
light irradiation (lexc=450 nm) in demineralized water under
an argon atmosphere. The initial absorption maximum at l=
460 nm decreased, and a metal-to-ligand charge transfer
(MLCT) band at l=474 nm increased over time; a clear iso-
sbestic point was also observed, which showed that a single
photoproduct was obtained under these conditions. According
to mass spectrometry analysis, the photoproduct was [1]2+ (m/
z calcd: 342.5; m/z found: 342.4). Photosubstitution of the thi-
oether glucose conjugate by water proceeds with a quantum
yield (F450) of 0.00095 (0.00002) in deoxygenated water
(Table 1). Usually, photosubstitution processes significantly
quench the emission of ruthenium polypyridyl complexes.
Indeed, the phosphorescence of [d-2][PF6]2 in phosphate buf-
fered saline (PBS) (pH 7.4) at lexc=450 nm in air was very
weak; the wavelength of the emission maximum was l=
648 nm, and a phosphorescence quantum yield (FP) of 3.7
105 was measured (Table 1). Under prolonged blue-light irradi-
ation in air, the wavelength of the emission band shifted from
l=648 to 690 nm, with consecutive formation of the weakly
emissive photoproduct [1]2+ (FP=3.210
5 ; Table 1). NIR
emission spectroscopy was also performed at lexc=450 nm to
check whether irradiation of [d-2]2+ in air would produce sin-
glet oxygen (1O2). In water, PBS, or D2O, no emission at l=
1270 nm was detected because of the very short lifetime of
1O2 in aqueous solution. However, in CD3OD an intense emis-
sion peak at l=1270 nm, characteristic of 1O2, was observed
upon blue-light irradiation of [d-2][PF6]2 (Figure S4 in the Sup-
porting Information). The quantum yield of 1O2 production
(FD) for [d-2][PF6]2 in CD3OD was 0.71 (Table 1), in other words,
[d-2][PF6]2 generates
1O2 very efficiently in air (Figure S4 in the
Supporting Information). The photoproduct [Ru(tpy)(dppn)(C-
D3OD)]
2+ , which was obtained after extensive blue-light irradia-
tion of [d-2]2+ in CD3OD, also generated
1O2 with a high FD
value (0.43; Table 1).
The photosubstitution of the thioether ligand d-3 in [d-2]2+
contrasts with recent work from the Turro group, who demon-
strated that the analogous complex [Ru(tpy)(dppn)(pyridine)]2+
did not undergo photosubstitution of the pyridine ligand in or-
ganic solvents. Instead, the complex was found to efficiently
produce 1O2 (FD=0.98) due to the presence of low-lying p–p*
excited states centered on the dppn ligand.[17] Therefore, the
nature of the monodentate ligand plays an important role in
the photoreactivity of this family of dppn-based ruthenium
Figure 1. Schematic representation of the light-induced dual mode-of-action
for glycoconjugated [d-2]2+ , in which d-3 is a thioether-glucose conjugate.
For clarity the l enantiomers are omitted.
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complexes. Although photosubstitution, phosphorescence,
and 1O2 generation often represent competing pathways in
ruthenium photochemistry, when [d-2]2+ is irradiated with
blue light all these processes may occur depending on the O2
concentration. Under deoxygenated conditions photosubstitu-
tion of the thioether ligand to form the aqua complex is pre-
ferred, whereas in air, efficient generation of 1O2 becomes
a competing pathway and is observed both before and after
photosubstitution.
Cytotoxicity assay
The cytotoxic properties of [d-2][PF6]2 and its enantiomer [l-2]
[PF6]2 were first tested in the dark on two human cancer cell
lines, A549 (human lung carcinoma) and MCF-7 (human breast
adenocarcinoma).[9] In parallel, considering the dual photoreac-
tivity of [d-2][PF6]2, the phototoxicity of [d-2][PF6]2 and [l-2]
[PF6]2 was also tested under a low dose of blue light (5 min at
l=45411 nm, 10.50.7 mWcm2, 3.20.2 Jcm2 ; see Ex-
perimental for full protocol). Briefly, cells were seeded at t=0
(5103 and 8103 cells/well for A549 and MCF-7, respectively),
treated with a concentration series of either [d-2][PF6]2 or [l-2]
Scheme 1. Synthesis of [d-2][PF6]2 and [l-2][PF6]2. a) Dppn (0.5 equiv), ethylene glycol, 5 h, 100 8C, 75%; b) i) AgNO3 (1.0 equiv), acetone/water (3:1), 50 8C,
ii) NH4PF6, 84%; c) d-3 (2.66 equiv), acetone, 50 8C, 24 h, 35%; d) l-3 (2.66 equiv), acetone, 50 8C, 24 h, 32%.
Figure 2. Electronic absorption spectra of [d-2][PF6]2 in deoxygenated H2O ir-
radiated at for 60 min. Spectra were taken every 30 s for the first 10 min,
and then every 5 min until 60 min. T=298 K, [Ru]tot=4.2310
5,
lexc=450 nm, photon flux=1.7710
7 Einstein s1. Insert depicts the evolu-
tion of ln[RuSRR]/[Ruu]tot vs. irradiation time (s), where [RuSRR] is the con-
centration of [2]2+ at irradiation time t and [Ru]tot the total ruthenium con-
centration.
Table 1. Lowest-energy absorption maxima and quantum yields for pho-
tosubstitution (F450),
1O2 production (FD), and phosphorescence (Fp) at
298 K.
Complex labs [nm]
[a]
(e [m1 cm1])
F450
[a] FD
[b] FP
[c]
[d-2]2+ 458 (11619) 0.000950.00002 0.71 0.000037
[1]2+ 475 (12643) – 0.43 0.000032
[a] In water under argon. [b] In CD3OD in air. [c] In PBS in air.
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[PF6]2 24 h after seeding, and then irradiated or maintained in
the dark after media refreshment 48 h after seeding. Cell viabil-
ity was assayed by using sulforhodamine B (SRB) 96 h after
seeding. The dose–response curves and effective concentra-
tions (EC50; the concentration of drug that gives a half-maxi-
mum effect) are shown in Figure 3 and Table 2, respectively.
Images of the dark and irradiated samples of cells treated with
A549 and MCF-7 (20 mm, [d-2][PF6]2) 96 h after seeding are
shown in Figures S15 and S16 (see the Supporting Informa-
tion).
In the dark the cytotoxicity of [d-2][PF6]2 and [l-2][PF6]2 was
significantly different for the A549 and MCF-7 cells. For [d-2]
[PF6]2 the effective concentration was 2.6 and 1.9 times lower
for the A549 and MCF-7 cells, respectively, than for [l-2][PF6]2
(Table 2). Both compounds were activated upon irradiation and
showed similarly high cytotoxicity, which was characterized by
submicromolar EC50 values. According to these results, the
chiral nature of the glucose functional group seems to have an
effect on the cytotoxicity of the non-irradiated prodrugs. In ad-
dition, upon light irradiation either the release of the photo-
product [1]2+ or efficient 1O2 generation by both enantiomers
of the prodrug [2]2+ and the activated drug [1]2+ , or both, re-
sults in a highly cytotoxic combination.[18]
Cellular localization and in vitro imaging
Contrary to the many ruthenium complexes capable of ligand
photosubstitution, [d-2][PF6]2 and [l-2][PF6]2 were slightly emis-
sive within the cells, which allowed uptake and localization
studies to be performed (Figure 4; and Figures S9–S14 in the
Supporting Information). Microscopy imaging was performed
for A549 cells treated in the dark with [d-2][PF6]2 or [l-2][PF6]2
for 4, 6, and 24 h (lexc=488 nm; Figure S9 in the Supporting
Information). These images revealed that, independent of the
incubation time, [d-2][PF6]2 and [l-2][PF6]2 displayed no signifi-
cant difference in localization or emission intensity. In addition,
both complexes were clearly localized outside the nucleus (Fig-
ures S9 and S10 in the Supporting Information). Co-localization
experiments performed with MitoTracker Deep Red (MTDR,
lexc=639 nm) were attempted after 6 h incubation (Figure S13
in the Supporting Information). Due to the weaker emission of
[1]2+ relative to MTDR, and the absorption of MTDR at l=
488 nm, it was impossible to quantitatively co-localize the
ruthenium compound and the dye unequivocally. However,
when added separately the ruthenium compound and MTDR
gave qualitatively very similar images at l=488 or 639 nm, re-
spectively (Figure 4). This suggested that the ruthenium com-
pound might localize in the mitochondria. To confirm localiza-
tion in the mitochondria, an experiment was designed in
which the cells were treated with [d-2][PF6]2 (25 mm) in the
presence of MTDR. MTDR images taken at lexc=639 nm
showed normal mitochondrial morphology (Figures S13B and
S13E in the Supporting Information). More images were taken
at l=488 nm (Figures S13C and S13F in the Supporting Infor-
mation), followed by a second set of MTDR images (at l=
639 nm, see Figures S13D and S13G in the Supporting Informa-
tion). The mitochondria of the cells irradiated at lexc=488 nm
were altered compared to the untreated cells and showed
bubble-like structures. Thus, treating the cells with a combina-
Figure 3. Cell viability of A549 and MCF-7 cells versus the log(concentration)
of [d-2][PF6]2 and [l-2][PF6]2 under dark and irradiated conditions. Data
points are the mean of three independent experiments (SD error bars).
Table 2. (Photo)cytotoxicity of [d-2][PF6]2 and [l-2][PF6]2 expressed as effective concentrations (EC50) in the dark and after irradiation with blue light, and
photocytotoxicity index (PI) values versus A549 and MCF-7 cells. +95% and 95% confidence intervals are also indicated (in mm).
A549 MCF-7
Complex EC50 dark
[a] EC50 454 nm
[b] PI[c] EC50 dark
[a] EC50 454 nm
[b] PI[c]
[d-2](PF6)2 19 +4.0 0.72 +0.16 26 9.6 +2.9 0.86 +0.21 11
3.3 0.13 2.3 0.17
[l-2](PF6)2 50 +17 0.58 +0.13 86 18 +3.8 0.61 +0.28 30
13 0.11 3.1 0.19
[a] Cells were incubated with the Ru complex for 24 h. [b] Cells were incubated with the Ru complex for 24 h, and the media was refreshed before irradia-
tion with blue light (5 min at lexc=450 nm with (3.20.2) J cm2). [c] PI=EC50(dark)/EC50(450nm).
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tion of ruthenium complex and l=488 nm light modified the
mitochondria structure. Mitochondria are known to have
a highly negative inner-membrane potential, which can be tar-
geted by cationic, lipophilic compounds.[18] Considering the
positive charge and lipophilic nature of [d-2][PF6]2 and [l-2]
[PF6]2 and the experimental facts highlighted above, we pro-
pose that both complexes target the mitochondria upon cross-
ing the plasma membrane.
Due to the lack of selective uptake of [d-2][PF6]2 versus [l-2]
[PF6]2 and the proposed localization in the mitochondria,
a final imaging experiment with sodium azide (NaN3) was per-
formed. Sodium azide is known to inhibit all energy-dependent
uptake mechanisms. Cells treated with NaN3 and [d-2][PF6]2 or
[l-2][PF6]2 did not show significant differences in uptake or lo-
calization (Figure S12 in the Supporting Information) relative to
cells that were only treated with ruthenium complex. Altogeth-
er, although the cytotoxicity of both enantiomers depends on
the chirality of the glucose moiety, these results support a glu-
cose-transporter- and energy-independent[19] uptake mecha-
nism in vitro.
Photochemistry with DNA
The mitochondria house double-stranded circular DNA, which
was very interesting given the mitochondrial localization and
the DNA light-switch capabilities of dppz (dipyrido-[3,2-a :2’,3’-
c]phenazine) analogues of [1]2+ .[20] Therefore, the photochem-
istry of [d-2][PF6]2 with calf thymus DNA (CT-DNA) and pUC19
plasmid DNA was studied in more detail. As explained above,
in PBS under blue-light excitation (lexc=450 nm) in air the
emission maximum of [d-2][PF6]2 shifted from l=648 to
690 nm, which was attributed to the formation of [1]2+ . Under
these conditions there was no significant change in the emis-
sion intensity over the irradiation time (Figure S6 in the Sup-
porting Information). However, under the same irradiation con-
ditions, but in the presence of CT-DNA, the emission shifted
from l=648 to 700 nm and the intensity increased 10-fold
over 25 min of irradiation (Figure S5B in the Supporting Infor-
mation). Under similar conditions, the presence of micelles
(Pluronic F-127), 1,2-dioleoyl-sn-glycero-3-phosphocholine
(DOPC) or 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC)
liposomes, l-cysteine, l-histidine, l-glutathione, l-lysine, l-tryp-
tophan, and 5’-guanosine monophosphate (5’-GMP) (5 mm in
PBS) did not enhance the emission after irradiation. These data
confirm a specific DNA light-switch interaction of [1]2+ with
CT-DNA and further support that the emission observed in the
cells is the result of interaction with DNA.
The emission study suggested different interactions of [d-
2]2+ and [1]2+ with DNA. To investigate this further, the inter-
action between [d-2][PF6]2 and pUC19 plasmid DNA was ana-
lyzed by agarose gel electrophoresis. pUC19 was supplied as
a 2686 base pairs (bp) plasmid, of which 95% was in the su-
percoiled (SC) form. A single nick in one of the SC strands,
caused by 1O2 for example, results in the open circular (OC)
form, which migrates more slowly through the gel than the SC
form. Staining and visualization of the DNA with ethidium bro-
mide (EtBr), a known DNA intercalator, was sensitive to the
ratio of DNA base pairs relative to the metal complex (bp/MC;
see Figure S7 in the Supporting Information). Thus, [d-2]2+ and
EtBr compete for the same DNA binding sites. To determine
the photobinding and photocleaving ability of [d-2]2+ , a 400:1
bp/MC ratio was used. At this low metal-complex concentra-
tion (5 mm), [d-2]2+ displayed minimal binding in the dark
and allowed DNA visualization by treatment with EtBr (Fig-
ure S7 in the Supporting Information). However, with increas-
ing light doses (lexc=450 nm, 1 min, 0.6 Jcm
2 to 15 min,
9.5 Jcm2) two phenomena were observed. First, an increased
volume of the OC form was observed at higher light doses,
which is a sign of 1O2 generation (Figure S8 in the Supporting
Information). Second, migration retardation of the SC form was
clearly observed. In our case, a limitation of DNA gel electro-
phoresis was that the specific mode of interaction (covalent
modification versus intercalation) could not be specified. How-
ever, it did show that photoinduced association of [1]2+ or [d-
2]2+ with the SC form occurred. Taking into account both sets
of DNA experiments, we propose that the photoproduct [1]2+
can interact with mitochondrial DNA either by intercalation or
coordination, which results in increased emission of the metal
complex and DNA photocleavage by formation of 1O2. Both
DNA binding and cleavage occur at very high bp/MC ratios rel-
ative to previously reported DNA light switches,[20,21] which
highlights the exceptional photodynamic properties of [1]2+ .
Conclusions
Glycoconjugation dramatically improves the hydrophilicity of
a compound, which also improves the drug properties of lipo-
philic compounds such as [1]2+ . Additionally, combining glyco-
conjugation with the light-induced uncaging properties of
ruthenium-based polypyridyl compounds, the hydrophobic
active molecule [1]2+ can be recovered inside the cell if the
glycoconjugated compound can still cross the cell membrane.
For [d-2][PF6]2 and [l-2][PF6]2 this approach was very success-
ful : the dppn ligand is lipophilic enough to counterbalance the
hydrophilicity of the glucose moiety, which allows passive
uptake to take place. Upon irradiation with a low dose of visi-
ble light (lexc=454 nm, 3.2 Jcm
2) a very high cytotoxic activi-
ty, characterized by submicromolar EC50 values, was obtained.
The significant phototoxic indices of these compounds may be
a consequence of at least two photochemical reactions occur-
ring in the mitochondria. First, photosubstitution of the thio-
ether glucose ligand in [d-2]2+ by water occurs, which allows
Figure 4. Microscope images of an A549 cell treated with: a) [d-2][PF6]2
(lexc=488 nm, cfinal=25 mm), b) MitoTracker deep red (lexc=639 nm,
cfinal=1.1 mm), and c) [l-2][PF6]2 (lexc=488 nm, cfinal=25 mm).
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better interaction of the photoproduct [1]2+ with biomole-
cules. In particular, mitochondrial DNA seems a likely target of
the achiral photoproduct [1]2+ because it interacts with plas-
mid DNA at a particularly high base pair/Ru ratio. Second, both
[2]2+ and [1]2+ efficiently generate 1O2, which leads to exten-
sive DNA photocleavage for adducts of mitochondrial DNA
and [1]2+ . To the best of our knowledge, these results repre-
sent the first practical demonstration that photosubstitution
and 1O2 generation can combine in vitro to create a dual
mode of action, resulting in highly efficient light-induced
cancer cell death.
The second function of glycoconjugation is to introduce
specific interactions between the (pro)drug and glucose-sensi-
tive enzymes. When increased cytotoxicities are measured for
d-glucose-appended drugs, for example versus their aglycon
analogues, they are often interpreted as a sign of glucose-
transporter-mediated uptake. A similar interpretation would
have led us to conclude that the higher dark cytotoxicity of [d-
2][PF6]2 versus [l-2][PF6]2 was the result of the d-glucose func-
tional group in [d-2][PF6]2 targeting the glucose transporters.
However, in vitro imaging showed no difference in uptake or
cellular localization between the two enantiomers, and addi-
tion of sodium azide indicated energy-independent drug
uptake. These results demonstrate that GLUT or SGLT are not
involved in the uptake of these compounds, and thus other
enzymes (for example, efflux pumps and/or glucosidases)[22]
must be responsible for the two-fold greater cytotoxicity of [d-
2][PF6]2 relative to [l-2][PF6]2 in the dark. This work also had un-
expected consequences: although [d-2][PF6]2—the complex
conjugated to the natural d-glucose moiety—would be ex-
pected to be the most interesting “targeted” enantiomer, [l-2]
[PF6]2—the complex conjugated to the non-natural l-glucose
moiety—actually shows a higher phototoxic index because of
its lower cytotoxicity in the dark. Ultimately, l-glucose derivati-
zation showed a better pharmacological outcome than func-
tionalization with d-glucose.
Experimental Section
Synthesis
General : Reagents were purchased from Sigma–Aldrich and used
without further purification. Benzo[i]dipyrido-[3,2-a :2’,3’-c]phena-
zine (dppn) was synthesized according to a literature procedure.[23]
2,2’:6’,2’’-Terpyridine (tpy) was purchased from ABCR GmbH & Co.
Dry solvents were collected from a Pure Solve MD5 dry solvent dis-
penser from Demaco. For all inorganic reactions solvents were de-
oxygenated by bubbling argon gas through the solution for
30 min. Flash chromatography was performed on silica gel (Screen-
ing devices B. V.) with a particle size of 40–64 mm and a pore size
of 60 . TLC analysis was performed on TLC aluminum foils with
a silica gel matrix (Supelco silica gel 60, 56524); plates were visual-
ized under a UV lamp (l=254 nm) after spraying with 10% H2SO4
in ethanol or with solution of NH4Mo7O24·4H2O (25 gL
1) and
NH4CeSO44·H2O (10 gL
1) in 10% H2SO4, followed by charring at
250 8C on a heating plate. Optical rotation measurements were
performed with a Propol automated polarimeter (sodium d-line,
l=589 nm) with a sample concentration of 10 mgmL1 (c=1),
unless stated otherwise. IR spectra were recorded with a PerkinElm-
er universal attenuated total reflectance (UATR; Single Reflection
Diamond) Spectrum Two instrument (n˜=4000–700 cm1; resolu-
tion=4 cm1). 1H and 13C NMR were recorded in [D6]acetone,
[D6]DMSO, MeOD, or CDCl3 with chemical shifts (d) reported rela-
tive to the solvent peak. HRMS were recorded by direct injection
(2 mL of a 2 mm solution in 50:50 water/acetonitrile and 0.1%
formic acid) into a mass spectrometer (Thermo Finnigan LTQ Orbi-
trap) equipped with an electrospray ion source in positive mode
(source voltage 3.5 kV, sheath gas flow 10, capillary temperature
250 8C) with resolution (R)=60000 at m/z 400 (mass range m/z
150–2000) and dioctyl phthalate (m/z 391.28428) as a lock mass.
The high-resolution mass spectrometer was calibrated prior to
measurements with a calibration mixture (Thermo Finnigan). Com-
bustion analysis was performed at Kolbe Mikrolab (Germany).
Ligand synthesis : A full description of the ligand syntheses and
the characterization data for the ligands is provided in the Sup-
porting Information.
Complex [4][Cl]: Ruthenium dimer [{RuCl2(tpy)}2]·H2O
[24] (300 mg,
0.347 mmol) and dppn[23] (231 mg, 0.695 mmol) were dissolved in
a deoxygenated solution of ethylene glycol (17 mL), and the mix-
ture was heated at 100 8C under an argon atmosphere for 5 h. The
resulting purple solution was filtered over Celite. Et2O (50 mL) was
added to the filtrate, and the resulting precipitate was collected on
a glass frit, thoroughly washed with water and Et2O, and then
dried under high vacuum to give [4][Cl] (383 mg, 0.473 mmol,
75%) as a purple powder. Rf=0.31 (10% MeOH/CH2Cl2) ;
1H NMR
(400 MHz, [D6]DMSO): d=10.42 (d, J=4.7 Hz, 1H; 1), 9.75 (d, J=
8.0 Hz, 1H; 3), 9.21–9.06 (m, 3H; 8, 22, 15), 8.90 (d, J=8.1 Hz, 2H;
T3’, T5’), 8.75 (d, J=8.1 Hz, 2H; T6, T6’’), 8.56 (dd, J=8.1, 5.4 Hz, 1H;
2), 8.38 (d, J=9.5 Hz, 1H; T3, T3’’), 8.30 (t, J=8.1 Hz, 1H; T4’’), 7.99
(t, J=8.1 Hz, 2H; T5, T5’’), 7.83 (d, J=5.4 Hz, 1H; 20), 7.78–7.65 (m,
4H; 10, 13, T4, T4’’), 7.53 (dd, J=8.1, 5.5 Hz, 1H; 21), 7.32 ppm (t,
J=6.7 Hz, 2H; 11, 12); 13C NMR (100 MHz, [D6]DMSO): d=158.4
(Cq), 157.6 (Cq), 154.0 (CH 1), 153.80 (CH 20), 152.6 (Cq), 152.5 (CH 10,
CH 13), 150.5 (Cq), 141.5 (Cq), 141.0 (Cq), 137.9 (Cq), 137.8 (Cq), 137.2
(CH T5, CH T5’’), 134.5 (Cq), 134.4 (Cq), 134.2 (CH T4’), 131.9 (CH 3),
130.8 (CH 8), 130.1 (Cq), 129.6 (Cq), 128.5 (CH T3), 128.5, 128.5 (CH
T3’’), 127.9 (CH 22), 127.8 (CH 15), 127.3 (CH T4, T4’’), 127.2 (CH 11, CH
12), 126.5 (CH 21), 123.7 (CH 21), 122.80 ppm (CH T3’, CH T5’) ; HRMS:
m/z calcd (%) for [C37H23N7ClRuCl]: 702.07415; found: 702.07439;
elemental analysis calcd (%) for C37H23N7Ru·4H2O: C 54.89, H 3.86,
N 12.11; found: C 53.63, H 3.83, N 11.61.
Complex [1][PF6]2 : AgNO3 (39.0 mg, 0.230 mmol) was added to
a solution of [4][Cl] (73.0 mg, 0.099 mmol) in 3:1 acetone/water
(10 mL). This mixture was stirred under an argon atmosphere at
50 8C for 16 h, and then filtered over Celite. A saturated aqueous
solution of NH4PF6 (2 mL) was added to the filtrate, and the result-
ing brown precipitate was collected on a glass frit then washed
with H2O (3) and Et2O (3) to afford [1][PF6]2 (60 mg, 0.083 mmol,
84%) as a brown precipitate, which was used without further pu-
rification. Rf=0.5 (100:80:20 acetone/water/saturated aqueous
KPF6).
Complex [d-2][PF6]2 : [1][PF6]2 (60.0 mg, 0.0668 mmol) and ligand
d-3 (61.0 mg, 0.178 mmol) were dissolved in deoxygenated ace-
tone, and the mixture was stirred at 50 8C for 24 h under an argon
atmosphere in the dark. The resulting brown/orange solution was
concentrated under vacuum at 30 8C in the dark. The crude materi-
al was purified by column chromatography on silica gel (acetone/
water/saturated aqueous KPF6 100:0:0 to 80:20:0 to 100:80:20), fol-
lowed by further purification by column chromatography on Se-
phadex LH-20 (acetone). The orange fraction was collected and the
volume was reduced to about 10% then Et2O was added. The re-
sulting precipitate was collected by filtration on a Whatman RC60
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membrane filter then washed with EtOAc (3), Et2O (3), and n-
hexane (3) to afford [d-2][PF6]2 (30 mg, 23 mmol, 35%) as an
orange powder. Rf=0.36 (16:4:1 acetone/water/saturated aqueous
KPF6) ;
1H NMR (400 MHz, [D6]acetone): d=10.39 (d, J=5.4 Hz, 1H;
1), 10.09 (d, J=8.2 Hz, 1H; 3), 9.60 (d, J=8.3 Hz, 1H; 22), 9.27 (s,
1H; 8), 9.15 (s, 1H; 15), 9.03 (d, J=8.2 Hz, 2H; T4’, T2’), 8.84 (d, J=
8.0 Hz, 2H; T5, T1’’), 8.73 (dd, J=8.3, 5.3 Hz, 1H; 2), 8.61 (t, J=
8.2 Hz, 1H; T3’), 8.44 (dd, J=18.7, 9.0 Hz, 2H; 11, 12), 8.19 (t, J=
7.9 Hz, 2H; T4, T2’’), 8.13 (t, J=3.7 Hz, 2H; T2, T4’’), 8.06 (d, J=
5.4 Hz, 1H; 20), 7.84–7.76 (m, 3H; 21, 10, 13), 7.47 (t, J=6.6 Hz,
2H; T3, T2’’), 4.31 (d, J=7.7 Hz, 1H; H-1), 4.23 (dd, J=12.9, 3.5 Hz,
1H; CHH H-6), 3.99–3.92 (m, 1H; OCHH), 3.86–3.76 (m, 1H; OCHH),
3.71–3.51 (m, 9H; CHH H-6, 2OCHH, 3OCH2), 3.41–3.23 (m, 3H;
H-3, H-4, H-5), 3.11 (td, J=8.2, 3.5 Hz, 1H; H-2), 2.26–2.18 (m, 2H;
OCH2SMe), 1.66 ppm (s, 3H);
13C NMR (100 MHz, [D6]acetone): d=
159.0 (Cq), 158.5 (Cq), 155.0 (CH 1), 153.2 (CH 1, CH T2, CH T4’’), 139.4
(CH T4, CH T2’’), 138.3 (CH T3’), 136.0 (Cq), 135.0 (CH 3) 134.7 (CH 22),
132.5 (Cq), 131.4 (Cq), 129.5 (CH T3, CH T2’’), 129.5, 129.5 (CH 11, CH
12) 129.1 (CH 8, CH 15), 128.9 (CH 11, CH 5, CH 8), 128.0 (Harom), 126.1
(CH T5, CH T1’’), 125.4 (CH T4’, CH T2’), 104.2 (C-1), 78.0 (C-3), 77.5 (C-
4), 74.8 (C-2), 71.7 (C-5), 71.0 (2OCH2), 70.9 (OCH2), 69.3 (OCH2),
68.2 (OCH2), 62.9 (C-6), 35.6 (OCH2SMe), 15.6 ppm (OCH2SMe) ;
HRMS: m/z calcd for [C50H49O8N7SRu2PF6]: 504.61979; found:
504.61993; elemental analysis calcd (%): C 46.23, H 3.80, N 7.55;
found: C 46.26, H 3.81, N 7.53.
Complex [l-2][PF6]2 : [l-2][PF6]2 was synthesized from ligand l-3
(94.0 mg, 0.0964 mmol) and purified according to the procedure
described for above for [d-2][PF6]2. This procedure afforded [l-2]
[PF6]2 (40 mg, 0.031 mmol, 32%) as an orange powder.
1H NMR and
HRMS data matched that reported for [d-2][PF6]2. Elemental analy-
sis calcd (%) for [l-2][PF6]2·H2O: C 45.60, H 3.90, N 7.44; found: C
45.70, H 4.06, N 7.32.
Photochemistry
A stock solution of [d-2][PF6]2 in demineralized water (c=4.23
105m, 3.00 mL) was transferred to a quartz fluorescence cuvette
(1 cm width) that contained a stirrer bar. This solution was deoxy-
genated for 15 min with argon then kept at a constant tempera-
ture (25 8C) and irradiated with light from a blue LED (lexc=
450 nm, full-width at half-maximum (FWHM)=19 nm) with photon
flux=1.77107 Einstein s1. During this period UV/Vis spectra
were recorded at intervals of 30 s for the first 10 min then every
5 min until 1 h. ESI-MS spectra were recorded after the irradiation
experiment to confirm the formation of the aqua species [Ru(t-
py)(dppn)(H2O)]
2+ . The quantum yield of photosubstitution (Fi)
was calculated according to Equation (1) by using l=490 and
410 nm as reference wavelengths, with e490=7220 and
12000m1 cm1 and e410=12660 and 10720m
1 cm1 for [d-2]
[PF6]2 and [1][PF6]2, respectively.
Fi ¼
kFi  nRuðtotÞ
F  ð1103AeÞ ð1Þ
in which kFi is the first-order photosubstitution rate constant,
nRuðtotÞ is the number of moles of ruthenium complex in the cuvette,
F is the photon flux determined by standard ferrioxalate actino-
metry, and Ae is the absorbance of the solution at the irradiation
wavelength. The quantum yield Fi was determined as an average
over two experiments ( standard deviation (SD)).
The 1O2 measurements and emission spectroscopy are described in
full detail in the Supporting Information.
Cell culturing and cytotoxicity assay
General : Human cancer cell lines A549 (human lung carcinoma)
and MCF-7 (human breast adenocarcinoma) were distributed by
the European Collection of Cell Cultures (ECACC), and purchased
from Sigma Aldrich. Dulbecco’s Modified Eagle Medium (DMEM,
with and without phenol red, without glutamine), Glutamine-S
(GM; 200 mm), trichloroacetic acid (TCA), glacial acetic acid, sulfo-
rhodamine B (SRB), and tris(hydroxylmethyl)aminomethane (Tris
base) were purchased from Sigma Aldrich. Fetal calf serum (FCS)
was purchased from Hyclone. Penicillin and streptomycin were
purchased from Duchefa and were diluted to give a penicillin/
streptomycin solution (P/S; 100 mgmL1). Trypsin and Opti-MEM
(without phenol red) were purchased from Gibco Life Technologies.
Trypan blue (0.4% in 0.81% sodium chloride and 0.06% potassium
phosphate dibasic solution) was purchased from BioRad. Plastic
disposable flasks and 96-well plates were purchased from Sarstedt.
Cells were counted by using a BioRad TC10 automated cell counter
with Biorad cell-counting slides. UV/Vis measurements for analysis
of 96-well plates were performed with a M1000 Tecan Reader. Cells
were inspected with an Olympus IX81 microscope.
Cell culturing : Cells were cultured in DMEM complete (DMEM with
phenol red, supplemented with FCS (8.0% v/v), P/S solution (0.2%
v/v), GM (0.9% v/v)). Cells were cultured under humidified condi-
tions (37 8C atmosphere containing 7.0% CO2) in 75 cm
2 flasks and
subcultured (1:3–1:6) upon reaching 70–80% confluency (approxi-
mately once per week). Media was refreshed every 2 d; cells were
passaged for 4–8 weeks.
Cell-irradiation setup : The cell-irradiation system consisted of a Di-
tabis thermostat (980923001) fitted with two flat-bottomed micro-
plate thermoblocks (800010600) and a 96-LED array fitted to a stan-
dard 96-well plate. The l=454 nm LED (OVL-3324), fans (40 mm,
24 V DC, 9714839), and power supply (EA-PS 2042-06B) were ob-
tained from Farnell. See Hopkins et al.[25] for a full description of
the cell-irradiation setup.
Cytotoxicity assay : Cells were seeded at t=0 in 96-well plates at
a density of 5103 (A549) and 8103 cells/well (MCF-7) in Opti-
MEM complete without phenol red (100 mL) and incubated for 24 h
at 37 8C/7% CO2. After this period, aliquots (100 mL) of six different
concentrations (1–100 mm for dark plates, 0.1–10 mm for irradiated
plates) of freshly prepared stock solutions of [d-2][PF6]2 and [l-2]
[PF6]2 in Opti-MEM were added to the wells in triplicate. Plates
were incubated in the dark for an additional 24 h. After this period
the media in each well was refreshed, and half of the plates were
irradiated for 5 min with blue light (l=45411 nm, power density
= 10.50.7 mWcm2, light dose = 3.20.2 Jcm2) and the other
half were kept in the dark under otherwise identical conditions.
After irradiation all the plates were placed incubated for an addi-
tional 48 h. The cells were fixed by adding cold TCA (10% w/v ;
100 mL) in each well. Next, TCA was removed from the wells, and
the plates were gently washed with water (5), air dried, stained
with SRB (0.6% w/v in acetic acid (1% v/v ; 100 mL) for 30–45 min,
washed with acetic acid (1% v/v ; 300 mL), and air dried. The SRB
dye was solubilized with Tris base (10 mm ; 200 mL), and the ab-
sorbance in each well was read at l=510 nm by using a M1000
Tecan Reader.
The SRB absorbance data was used to calculate the fraction of
viable cells in each well (Excel and GraphPad Prism software). The
absorbance data were averaged from triplicate wells per concen-
tration. Relative cell viabilities were calculated by dividing the aver-
age absorbance of the treated wells by the average absorbance of
the untreated wells. Three independent biological replicates were
completed for each cell line (three different passage numbers per
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cell line). The average cell viability of the three biological replicates
was plotted versus log(concentration) [mm] , with the SD error of
each point. By using the dose–response curve for each cell line
under dark- and irradiated conditions, the effective concentration
(EC50) was calculated by fitting the curves to a non-linear regres-
sion function with fixed y maximum (100%) and minimum (0%)
(relative cell viability) and a variable Hill slope, which resulted in
the simplified two-parameter Hill-slope equation [Eq. (2)]:
100
ð1þ10ððlog10EC50XÞHill SlopeÞÞ ð2Þ
The DNA photointeraction studies and (emission) microscopy are
described in full detail in the Supporting Information.
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d- Versus l-Glucose Conjugation:
Mitochondrial Targeting of a Light-
Activated Dual-Mode-of-Action
Ruthenium-Based Anticancer Prodrug
Illuminating! Two enantiomeric rutheni-
um–glucose thioether complexes (see
figure) showed mild but different cyto-
toxicity in A549 (human lung carcino-
ma) and MCF-7 (human breast adeno-
carcinoma) cancer cells in the dark,
whereas similarly high cytotoxicities
were observed following low doses of
visible-light irradiation.
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